BCL2 and prostate carcinoma: In this context, one study demonstrated that 22Rv1 cells exhibit nearly undetectable BAX protein levels and that blocking Akt, which targets the BCL-2 signaling pathway, sensitizes castration-resistant prostate cancer cells to enzalutamide [53].